Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro

Journal of Molecular and Cellular Cardiology

Volumn 37, Issue 4, 2004, Pages 837-846

  Spallarossa, Paolo ^a   Garibaldi, Silvano ^a   Altieri, Paola ^a   Fabbi, Patrizia ^a   Manca, Valeria ^a   Nasti, Sabina ^a   Rossettin, Pierfranco ^a   Ghigliotti, Giorgio ^a   Ballestrero, Alberto ^a   Patrone, Franco ^a   Barsotti, Antonio ^a   Brunelli, Claudio ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Adrenergic antagonist; Apoptosis; Cardiomyocytes; Cardiomyopathy; Carvedilol; Doxorubicin; Free radicals

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; CASPASE 3; DICHLOROFLUORESCEIN; DNA FRAGMENT; DOXORUBICIN; FLUORESCEIN ISOTHIOCYANATE; FREE RADICAL; HYDROETHIDINE; LIPOCORTIN 5; MESSENGER RNA; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CARDIOTOXICITY; CELL CULTURE; CONTROLLED STUDY; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE EXPRESSION; HEART MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STATISTICAL SIGNIFICANCE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIOXIDANTS; APOPTOSIS; ATENOLOL; BCL-2-ASSOCIATED X PROTEIN; CARBAZOLES; CASPASE 3; CASPASES; CELLS, CULTURED; DNA FRAGMENTATION; DOXORUBICIN; FREE RADICALS; GENE EXPRESSION; MYOCYTES, CARDIAC; PROPANOLAMINES; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RNA, MESSENGER;

EID: 4544228968     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2004.05.024     Document Type: Article

References (45)

1. Orhan B. Doxorubicin cardiotoxicity: growing importance. J Clin Oncol. 17:1999;2294-2296
2. Silber J.H., Barber G. Doxorubicin-induced cardiotoxicity. New Engl J Med. 333:1995;1359-1360
3. Ewer M.S., Jaffe N., Ried H., Zietz H.A., Benjamin R.S. Doxorubicin cardiotoxicity in children: comparison of a consecutive divided daily dose administration schedule with single dose (rapid) infusion administration. Med Pediatr Oncol. 31:1998;512-515
4. Yeung T.K., Chakrabarti K., Wilding D., Hopewell J.W. Modification of doxorubicin-induced cardiotoxicity: manipulation of the dosage schedule. Hum Exp Toxicol. 21:2002;607-614
5. Mitani I., Jain D., Joska T.M., Burtness B., Zaret B.L. Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era. J Nucl Cardiol. 10:2003;132-139
6. Horenstein M.S., Vander Heide R.S., L'Ecuyer T.J. Molecular basis of anthracycline-induced cardiotoxicity and its prevention. Mol Genet Metab. 71:2000;436-444
7. Kotamraju S., Konorev E.A., Joseph J., Kalyanaraman B. Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. Role of reactive oxygen and nitrogen species. J Biol Chem. 275:2000;33585-33592
8. Dorr R.T. Cytoprotective agents for anthracyclines. Semin Oncol. 4:(Suppl 8):1996;23-34
9. Van Vleet J.F., Ferrans V.J., Weirich W.E. Cardiac disease induced by chronic adriamycin administration in dogs and an evaluation of vitamin E and selenium as cardioprotectants. Am J Pathol. 99:1980;13-42
10. Kumar D., Kirshenbaum L.A., Li T., Danelisen I., Singal P.K. Apoptosis in adriamycin cardiomyopathy and its modulation by probucol. Antioxid Redox Signal. 3:2001;135-145
11. Liu X., Chen Z., Chua C.C., Ma Y.S., Youngberg G.A., Hamdy R., et al. Melatonin as an effective protector against doxorubicin-induced cardiotoxicity. Am J Physiol Heart Circ Physiol. 283:2002;H254-H263
12. Yamanaka S., Tatsumi T., Shiraishi J., Mano A., Keira N., Matoba S., et al. Amlodipine inhibits doxorubicin-induced apoptosis in neonatal rat cardiac myocytes. J Am Coll Cardiol. 41:2003;870-878
13. Frishman W.H. Carvedilol. New Engl J Med. 339:1998;1759-1765
14. Feuerstein G., Ruffolo R.R. Jr. Beta-blockers in congestive heart failure: the pharmacology of carvedilol, a vasodilating beta-blocker and antioxidant, and its therapeutic utility in congestive heart failure. Adv Pharmacol. 42:1998;611-615
15. Feuerstein G.Z., Ruffolo R.R. Jr. Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Eur Heart J. 16:(Suppl F):1995;38-42
16. Noguchi N., Nishino K., Niki E. Antioxidant action of the antihypertensive drug, carvedilol, against lipid peroxidation. Biochem Pharmacol. 59:2000;1069-1076
17. Yue T.L., Ma X.L., Wang X., Romanic A.M., Liu G.L., Louden C., et al. Possible involvement of stress-activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia/reperfusion-induced cardiomyocyte apoptosis by carvedilol. Circ Res. 82:1998;166-174
18. Fazio S., Palmieri E.A., Ferravante B., Bone F., Biondi B., Sacca L. Doxorubicin-induced cardiomyopathy treated with carvedilol. Clin Cardiol. 21:1998;777-779
19. Billingham M.E., Mason J.W., Bristow M.R., Daniels J.R. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep. 62:1978;865-872
20. 2 in cultured endothelial cells. Arch Biochem Biophys. 302:1993;348-355
21. Benov L., Sztejnberg L., Fridovich I. Critical evaluation of the use of hydroethidine as a measure of superoxide anion radical. Free Radic Biol Med. 25:1998;826-831
22. Arends M.J., Morris R.G., Wyllie A.H. Apoptosis. The role of the endonuclease. Am J Pathol. 136:1990;593-608
23. Wu S., Ko Y.S., Teng M.S., Ko Y.L., Hsu L.A., Hsueh C., et al. Adriamycin-induced cardiomyocyte and endothelial cell apoptosis: in vitro and in vivo studies. J Mol Cell Cardiol. 34:2002;1595-1607
24. Shintaku S., Ohdan H., Yamamoto H., Miyata Y., Hayashi A., Ito H., et al. Expression of bcl-2 homologue mRNAs in rat liver allograft: rejection-induced cell apoptosis is associated with upregulation of bax and bcl-xs expression. Transpl Int. 11:1998;S284-S288
25. Zaugg M., Jamali N.Z., Lucchinetti E., Xu W., Alam M., Shafiq S.A., et al. Anabolic-androgenic steroids induce apoptotic cell death in adult rat ventricular myocytes. J Cell Physiol. 187:2001;90-95
26. Sawyer D.B., Fukazawa R., Arstall M.A., Kelly R.A. Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane. Circ Res. 84:1999;257-265
27. Ubezio P., Civoli F. Flow cytometric detection of hydrogen peroxide production induced by doxorubicin in cancer cells. Free Radic Biol Med. 16:1994;509-516
28. Yuan L., Inoue S., Saito Y., Nakajima O. An evaluation of the effects of cytokines on intracellular oxidative production in normal neutrophils by flow cytometry. Exp Cell Res. 209:1993;375-381
29. Bindokas V.P., Jordan J., Lee C.C., Miller R.J. Superoxide production in rat hippocampal neurons: selective imaging with hydroethidine. J Neurosci. 16:1996;1324-1336
30. Green P.S., Leeuwenburgh C. Mitochondrial dysfunction is an early indicator of doxorubicin-induced apoptosis. Biochim Biophys Acta. 1588:2002;94-101
31. Antonsson B., Martinou J.C. The Bcl-2 protein family. Exp Cell Res. 256:2000;50-57
32. Crompton M. Bax, bid and the permeabilization of the mitochondrial outer membrane in apoptosis. Curr Opin Cell Biol. 12:2000;414-419
33. Yang J., Liu X., Bhalla K., Kim C.N., Ibrado A.M., Cai J., et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science. 275:1997;1129-1132
34. Wang L., Ma W., Markovich R., Chen J.W., Wang P.H. Regulation of cardiomyocyte apoptotic signaling by insulin-like growth factor I. Circ Res. 83:1998;516-522
35. Childs A.C., Phaneuf S.L., Dirks A.J., Phillips T., Leeuwenburgh C. Doxorubicin treatment in vivo causes cytochrome c release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax ratio. Cancer Res. 62:2002;4592-4598
36. Kumar D., Kirshenbaum L., Li T., Danelisen I., Singal P. Apoptosis in isolated adult cardiomyocytes exposed to adriamycin. Ann NY Acad Sci. 874:1999;156-168
37. Matsui H., Morishima I., Numaguchi Y., Toki Y., Okumura K., Hayakawa T. Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats. Life Sci. 65:1999;1265-1274
38. Iwai-Kanai E., Hasegawa K., Araki M., Kakita T., Morimoto T., Sasayama S. Alpha- and beta-adrenergic pathways differentially regulate cell type-specific apoptosis in rat cardiac myocytes. Circulation. 100:1999;305-311
39. Zaugg M., Xu W., Lucchinetti E., Shafiq S.A., Jamali N.Z., Siddiqui M.A. Beta-adrenergic receptor subtypes differentially affect apoptosis in adult rat ventricular myocytes. Circulation. 102:2000;344-350
40. Venturini M., Michelotti A., Del Mastro L., Gallo L., Carnino F., Garrone O., et al. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J Clin Oncol. 14:1996;3112-3120
41. Noori A., Lindenfeld J., Wolfel E., Ferguson D., Bristow M.R., Lowes B.D. Beta-blockade in adriamycin-induced cardiomyopathy. J Card Fail. 6:2000;115-119
42. Lekakis J., Prassopoulos V., Athanassiadis P., Kostamis P., Moulopoulos S. Doxorubicin-induced cardiac neurotoxicity: study with iodine 123-labeled metaiodobenzylguanidine scintigraphy. J Nucl Cardiol. 3:1996;37-41
43. Agostini D., Belin A., Amar M.H., Darlas Y., Hamon M., Grollier G., et al. Improvement of cardiac neuronal function after carvedilol treatment in dilated cardiomyopathy: a 123I-MIBG scintigraphic study. J Nucl Med. 41:2000;845-851
44. McPhillips J.J., Schwemer G.T., Scott D.I., Zinny M., Patterson D. Effects of carvedilol on blood pressure in patients with mild to moderate hypertension. A dose-response study. Drugs. 36:(Suppl 6):1988;82-91
45. Yue T.L., Ma X.L., Gu J.L., Ruffolo R.R. Jr, Feuerstein G.Z. Carvedilol inhibits activation of stress-activated protein kinase and reduces reperfusion injury in perfused rabbit heart. Eur J Pharmacol. 345:1998;61-65